ACE-083 + ACE-083 or placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Facioscapulohumeral Muscular Dystrophy
Conditions
Facioscapulohumeral Muscular Dystrophy
Trial Timeline
Nov 1, 2016 → Oct 9, 2019
NCT ID
NCT02927080About ACE-083 + ACE-083 or placebo
ACE-083 + ACE-083 or placebo is a phase 2 stage product being developed by Merck for Facioscapulohumeral Muscular Dystrophy. The current trial status is terminated. This product is registered under clinical trial identifier NCT02927080. Target conditions include Facioscapulohumeral Muscular Dystrophy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02927080 | Phase 2 | Terminated |
Competing Products
12 competing products in Facioscapulohumeral Muscular Dystrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ACE-083 | Merck | Phase 2 | 52 |
| Placebo + RO7204239 | Roche | Phase 2 | 52 |
| AOC-1020 + Placebo | Avidity Biosciences | Phase 3 | 74 |
| Apitegromab + Placebo | Scholar Rock Holding | Phase 2 | 49 |
| Losmapimod oral tablet + Placebo oral tablet | Fulcrum Therapeutics | Phase 2 | 44 |
| Losmapimod + Placebo oral tablet | Fulcrum Therapeutics | Phase 3 | 69 |
| Losmapimod | Fulcrum Therapeutics | Phase 2 | 44 |
| Losmapimod | Fulcrum Therapeutics | Phase 2 | 44 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |
| Placebo + ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |